The impact of glutathione on pulmonary function remains elusive for patients with cystic fibrosis. The present study is a systematic review and meta-analysis. Researchers did this study to explore glutathione’s influence versus placebo on cystic fibrosis’s pulmonary function.

Researchers searched five online platforms that included PubMed, EMbase, Web of Science, EBSCO, Cochrane library databases, and RCTs regarding glutathione’s effect on cystic fibrosis pulmonary function were included in this meta-analysis.

The sample size consisted of four RCTs. The clinical sample was compared with the control group, and analysis revealed that glutathione treatment shows a positive impact on forced expiratory volume 1 second (FEV1) (mean difference [MD] = 0.19; 95% confidence interval (CI), 0.10–0.28; P < .0001) and body mass index, but has no apparent influence on 6-minute walk test (standard MD = 0.28; 95% CI, −0.08 to 0.64; P = .13), number of exacerbations (MD = −0.10; 95% CI, −0.34 to 0.15; P = .43), abdominal pain or distal intestinal obstruction, or hemoptysis.

The study concluded that glutathione treatment provides some benefits to improve patients’ pulmonary function with cystic fibrosis, as evidenced by the increase in FEV1.